[Treatment of Alzheimer's disease: status quo and future considerations].
Shimohama
Shun
S
D000109:Acetylcholine / Q000502:physiology; D000544:Alzheimer Disease / Q000209:etiology* / Q000517:prevention & control / Q000523:psychology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D001526:Behavioral Symptoms; D002794:Choline / Q000031:analogs & derivatives / Q000502:physiology; D002800:Cholinesterase Inhibitors; D003071:Cognition; D000077265:Donepezil; D015195:Drug Design; D005702:Galantamine; D018698:Glutamic Acid / Q000633:toxicity; D006801:Humans; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D012307:Risk Factors; D000068836:Rivastigmine
D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate; D005702:Galantamine; C017100:butyrylcholine; D018698:Glutamic Acid; D000077265:Donepezil; D002794:Choline; D000109:Acetylcholine; D000068836:Rivastigmine